These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25748895)

  • 1. Amgen's bispecific antibody puffs across finish line.
    Sheridan C
    Nat Biotechnol; 2015 Mar; 33(3):219-21. PubMed ID: 25748895
    [No Abstract]   [Full Text] [Related]  

  • 2. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
    Schmidt C
    Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
    Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
    Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promotion of natural killer cell growth in vitro by bispecific (anti-CD3 x anti-CD16) antibodies.
    Malygin AM; Somersalo K; Timonen T
    Immunology; 1994 Jan; 81(1):92-5. PubMed ID: 7510664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative triggering molecules and single chain bispecific antibodies.
    Segal DM; Sconocchia G; Titus JA; Jost CR; Kurucz I
    J Hematother; 1995 Oct; 4(5):377-82. PubMed ID: 8581372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can 'double blockbuster' strengthen Amgen's backbone?
    Sheridan C
    Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
    [No Abstract]   [Full Text] [Related]  

  • 10. Bispecific antibodies and diabodies for cancer immunotherapy.
    Elsässer-Beile U; Bühler P
    Immunotherapy; 2012 May; 4(5):459-60. PubMed ID: 22642325
    [No Abstract]   [Full Text] [Related]  

  • 11. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.
    Zeidler R; Mysliwietz J; Csánady M; Walz A; Ziegler I; Schmitt B; Wollenberg B; Lindhofer H
    Br J Cancer; 2000 Jul; 83(2):261-6. PubMed ID: 10901380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boehringer splashes out on bispecific antibody platforms.
    Moran N
    Nat Biotechnol; 2011 Jan; 29(1):5-6. PubMed ID: 21221079
    [No Abstract]   [Full Text] [Related]  

  • 13. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
    Bruenke J; Fischer B; Barbin K; Schreiter K; Wachter Y; Mahr K; Titgemeyer F; Niederweis M; Peipp M; Zunino SJ; Repp R; Valerius T; Fey GH
    Br J Haematol; 2004 Apr; 125(2):167-79. PubMed ID: 15059139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysis of small cell carcinoma of the lung (SCCL) cells by cytokine-activated monocytes and natural killer cells in the presence of bispecific immunoconjugates containing a gastrin-releasing peptide (GRP) analog or a GRP antagonist.
    Chen J; Zhou JH; Mokotoff M; Fanger MW; Ball ED
    J Hematother; 1995 Oct; 4(5):369-76. PubMed ID: 8581371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buy buy bispecific antibodies.
    Holmes D
    Nat Rev Drug Discov; 2011 Oct; 10(11):798-800. PubMed ID: 22037028
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of a bispecific antibody tetramerized through hetero-associating peptides.
    Osaki T; Fujisawa S; Kitaguchi M; Kitamura M; Nakanishi T
    FEBS J; 2015 Nov; 282(22):4389-401. PubMed ID: 26337767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Ring DB; Alpaugh RK
    J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibody pipeline moves beyond oncology.
    Mullard A
    Nat Rev Drug Discov; 2017 Sep; 16(10):666-668. PubMed ID: 28959948
    [No Abstract]   [Full Text] [Related]  

  • 20. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.